GlaxoSmithKline

GSK's Blenrep receives Breakthrough Therapy Designation in China for relapsed or refractory multiple myeloma treatment based on DREAMM-7 trial results, showing significant PFS improvements over standard care.

GSK's phase II trial for mRNA seasonal flu vaccine met success criteria in both younger and older adults, showing acceptable safety and reactogenicity. The mRNA platform elicited strong antibody responses, prompting progression to late-stage development. GSK aims to create a best-in-class vaccine for greater flu protection.

The 'Migraine: Seven-Market Drug Forecast and Market Analysis' report, added to ResearchAndMarkets.com's offering, forecasts the migraine market in the US, France, Germany, Italy, Spain, the UK, and Japan to grow from $9.2 billion in 2023 to $16.4 billion by 2033, driven by a 6.0% CAGR. The report covers epidemiology, treatment options, unmet needs, pipeline analysis, and market competition.

Fulcrum Therapeutics' stock dropped >60% after its Phase 3 REACH trial for losmapimod, a potential FSHD treatment, missed its primary endpoint, leading to the suspension of the program.

A.A. (UCSF, NIH T32 grant, past consulting income from LeMaitre and MIS Technologies) and D.R. (FDA) have no conflicts of interest. L.H.C. (Duke, FDA, past consulting income from Regeneron, NFLPA, Boehringer, institutional grants from GSK, Novartis) also has no conflicts. R.M.C. (FDA, former Verily Life Sciences, Google Health employee, held equity, served on boards of Cytokinetics, Centessa, Clinetic, Keystone Symposia, C-Path, Clinical Research Forum, One Fifteen) discloses no conflicts related to this manuscript.

GSK's Blenrep granted Breakthrough Therapy Designation in China for relapsed or refractory multiple myeloma treatment, based on DREAMM-7 trial results.

GSK reports positive interim Phase II trial results for its mRNA-based multivalent influenza vaccine candidate, GSK4382276A, meeting pre-defined success criteria in both younger and older adult groups. The vaccine, encoding antigens matched to WHO-recommended influenza strains, showed potential for improved immune responses compared to current vaccines, prompting GSK to advance the programme into late-stage clinical development.

GSK granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma, based on DREAMM-7 trial results.

Moderna delays break-even goal to 2028, expects 2025 sales below 2024 forecast, and plans to cut $1.1 billion in R&D costs from 2026. The company cites challenges in launching new products and slower-than-expected RSV vaccine adoption.